Cegfila (previously Pegfilgrastim Mundipharma)

<p>Cegfila is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer chemotherapy and can leave patients vulnerable to infections.</p><p>It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever due to an infection).</p><p>Cegfila is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).</p><p>Cegfila is a ‘biosimilar medicine’. This means that Cegfila is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Cegfila is Neulasta.</p><p>Cegfila contains the active substance pegfilgrastim.</p>